• 1
    Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:20432050.
  • 2
    Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124:10461058.
  • 3
    Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360: 19031913.
  • 4
    Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension. 2009;54:690697.
  • 5
    Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953;152: 15011504.
  • 6
    DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75197.
  • 7
    Harris SH. Renal sympathectomy: its scope and limitations: (section of urology). Proc R Soc Med. 1935;28:14971510.
  • 8
    Hoobler SW, Manning JT, Paine WG, et al. The effects of splanchnicectomy on the blood pressure in hypertension; a controlled study. Circulation. 1951;4:173183.
  • 9
    Cohen DL, Townsend RR. Renal denervation revisited: promising treatment for resistant hypertension? J Clin Hypertens (Greenwich). 2011;13:931932.
  • 10
    Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:12751281.
  • 11
    Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932934.
  • 12
    Symplicity HTNI, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:19031909.
  • 13
    Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010 Dec 4;376(9756):19031909. Epub 2010 Nov 17.
  • 14
    Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-Based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012;35: 528535.
  • 15
    Ouzan J, Perault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002;15(4 pt 1):333339.
  • 16
    Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens. 2008;2:462468.
  • 17
    Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009;30:418424.
  • 18
    Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011;57:10761080.
  • 19
    de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898902.
  • 20
    Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60: 419424.
  • 21
    Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23: 12501257.
  • 22
    Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559565.
  • 23
    Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59:901909.
  • 24
    Schmieder RE, Redon J, Grassi G, et al. ESH position paper: renal denervation—an interventional therapy of resistant hypertension. J Hypertens. 2012;30:837841.
  • 25
    Rippy MK, Zarins D, Barman NC, et al. Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety. Clin Res Cardiol. 2011;100:10951101.
  • 26
    Thomas G, Shishehbor MH, Bravo EL, et al. Renal denervation to treat resistant hypertension: Guarded optimism. Cleve Clin J Med. 2012;79:501510.
  • 27
    DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298:R245R253.
  • 28
    Stefanadis C, Toutouzas K, Synetos A, Tsioufis C, Karanasos A, Agrogiannis G, Stefanis L, Patsouris E, Tousoulis D. Int J Chemical denervation of the renal artery by vincristine in swine. A new catheter based technique. Cardiol. 2012 Jan 20. [Epub ahead of print]
  • 29
    Mabin T, Sapoval M, Cabane V, et al. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. EuroIntervention. 2012;8:5761.